🇺🇸 FDA
Pipeline program

LX6171 High Dose

LX6171.1-201-AAMI

Phase 2 small_molecule completed

Quick answer

LX6171 High Dose for Age-Related Memory Disorders is a Phase 2 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LEXICON PHARMACEUTICALS, INC.
Indication
Age-Related Memory Disorders
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials